URMC Leads Moderna COVID-19 Vaccine Trial for Children 6 Months to 12 Years
The University of Rochester Medical Center (URMC) is playing a crucial role in the fight against COVID-19, participating in a clinical trial of the Moderna vaccine for children aged 6 months to 12 years. Meanwhile, interim data from Pfizer-BioNTech's trial shows 100% effectiveness in adolescents aged 12-15.
The Pfizer-BioNTech trial involved 2,260 adolescents, with none of the vaccinated group contracting COVID-19, compared to 18 cases in the placebo group. The vaccine elicited a strong immune response and was safe and well-tolerated. Pfizer and BioNTech have started trials in children aged 5 to 10 and plan to expand to lower age groups soon. At URMC, the Moderna trial is led by Dr. Mary Caserta and Dr. Jennifer Nayak, expected to launch in the spring.
Dr. Ann Falsey, a professor at URMC, finds the data encouraging, deeming the vaccine safe and efficacious. Dr. Mary Caserta is optimistic about further trials in younger age groups. Both companies aim to submit their data to the FDA to expand emergency use authorization.
These trials mark significant steps towards protecting younger populations against COVID-19. URMC's involvement in the Moderna trial for children aged 6 months to 12 years is expected to yield valuable data, contributing to the global effort to combat the pandemic.
Read also:
- Trump's SNAP reductions and New York City Council's grocery delivery legislation: Problems for city residents highlighted
- Reducing dental expenses for elderlies in Sweden: Over 50% cut in charges for pensioners by the government
- Forty-year-old diet: A list of meal choices to savor
- Exiled Life's Conundrum: A Blend of Liberation, Disillusionment, and Distress
